Termination of co-promotion agreement on Recomodulin™
anticoagulant intravenous infusion 12800
Asahi Kasei Pharma Corp.
Pfizer Japan Inc.
Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter “Asahi Kasei Pharma”) and Pfizer Japan Inc. (Shibuya-ku, Tokyo, Japan; President: Ichiro Umeda; hereinafter “Pfizer”) have reached a decision to end their co-promotion agreement in Japan for Recomodulin™ anticoagulant intravenous infusion 12800 (recombinant thrombomodulin alpha) which is manufactured and sold by Asahi Kasei Pharma, on March 31, 2016.
Asahi Kasei Pharma and Pfizer began co-promotion of Recomodulin™ in Japan on November 1, 2013. With the termination of the co-promotion agreement, promotion activities will be performed by Asahi Kasei Pharma alone from April 1, 2016, onward.